Ilya Tsimafeyeu is a medical oncologist with a focus on genitourinary malignancies and serves as Director of the Bureau for Cancer Research (BUCARE), an independent initiative involved in clinical research, real-world evidence generation, and oncology registries. Through BUCARE, he has supported observational studies and data collection efforts aimed at understanding treatment patterns and outcomes in kidney, bladder, and prostate cancers, particularly across Eastern Europe and Central Asia.
Dr. Tsimafeyeu has participated in and coordinated multiple clinical research projects and registries, including real-world studies designed to complement data from randomized trials in genitourinary oncology. His work emphasizes pragmatic research approaches, long-term outcome tracking, and the integration of clinical data into routine practice. In parallel, he has contributed to professional development in oncology, serving on the American Society of Clinical Oncology (ASCO) Regional Council and co-founding the Russian Society of Clinical Oncology (RUSSCO). He has also been active in initiatives addressing physician well-being, including international surveys examining burnout among oncology professionals.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential CEOs in Oncology in 2025 and stay tuned for other special category nominations
